Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017Licensed LMB-100, a Clinical-Stage Candidate for Mesothelioma and Pancreatic Cancer, from the National Cancer Institute...
-
Selecta Applies SVP™ Technology for Immune Stimulation to Address Significant Public Health IssueProgram Being Funded Primarily by U.S. National Institutes of Health (NIH) WATERTOWN, Mass., May 11,...
-
WATERTOWN, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
-
NCI Currently Conducting Clinical Trials with LMB-100LMB-100 and SVP-Rapamycin Combination Treatment Enhances Anti-Tumor Activity in Preclinical Models Selecta and NCI in Discussions Regarding Phase...
-
WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies that avoid unwanted...
-
WATERTOWN, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
-
WATERTOWN, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
-
New Data from Ongoing SEL-212 Phase 2 Trial Show Persistent Clinical Activity After Repeat Administration in Symptomatic Gout Patients Emerging Clinical and Preclinical Data Confirm the Broad...
-
WATERTOWN, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
-
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc....